Francis Mackie > Browne Jacobson LLP > London, England > Lawyer Profile

Browne Jacobson LLP
15TH FLOOR
6 BEVIS MARKS
LONDON
EC3A 7BA
England

Work Department

Business & Professional Risk

Position

Francis has over 30 years of experience in the London (re)insurance market. He joined Browne Jacobson in February 2017 as Partner based in the London office.

His experience covers a wide range of insurance and reinsurance sectors, mainly dealing with dispute, advice and overage issues, with particular experience in energy, professional indemnity, political risks/contract frustration, commercial property, financial institutions/D&O, pharmaceutical/product liability, contingency risks, binding authorities/MGA’s and a range of reinsurances such as the excess of loss market .

His practice is well known in the London Market and International Arbitration arena, where he has run arbitrations in London, Bermuda, and the US and Europe. His dispute practice also includes significant London Commercial Court cases/disputes over the years.

Career

  • Edwards Wildman – 2010 – 2014
  • Weightmans LLP – 2014 to February 2017  

Memberships

  • Member of BILA (through Browne Jacobson)
  • Member of the Insurance Committee of the CLLS

Education

  • Newcastle University – LLB

Lawyer Rankings

London > Insurance > Insurance and reinsurance litigation

Browne Jacobson LLP is well-reputed across the London and international insurance market, drawing on its exclusive membership within the Harmonie Group, which is a global network of independent specialist insurance firms. Core areas of strength for the team include COVID-19 business interruption claims, construction, coverholder issues and reinsurance. A specialist in professional liability and insurance coverage disputes, Jonathan Newbold heads up the financial and professional risks group across the firm’s UK offices. Other recommended individuals include Colin Peck for large-scale property damage and business interruption claims, and Francis Mackie for energy, professional indemnity, political risk and pharmaceutical/product liability matters.